(19)
(11) EP 2 680 885 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.07.2018 Bulletin 2018/30

(45) Mention of the grant of the patent:
30.05.2018 Bulletin 2018/22

(21) Application number: 12709382.1

(22) Date of filing: 02.03.2012
(51) International Patent Classification (IPC): 
A61K 39/095(2006.01)
A61K 39/295(2006.01)
A61K 33/06(2006.01)
A61K 31/4375(2006.01)
A61K 39/39(2006.01)
A61K 39/13(2006.01)
A61K 39/00(2006.01)
A61K 33/08(2006.01)
A61K 31/66(2006.01)
A61K 33/42(2006.01)
(86) International application number:
PCT/IB2012/050989
(87) International publication number:
WO 2012/117377 (07.09.2012 Gazette 2012/36)

(54)

COMBINATION VACCINES WITH LOWER DOSES OF ANTIGEN AND/OR ADJUVANT

KOMBINATIONSVAKZINE MIT NIEDRIGEN DOSEN AN ANTIGEN UND/ODER ADJUVANS

VACCINS COMBINÉS COMPRENANT DES DOSES INFÉRIEURES D'ANTIGÈNE ET/OU D'ADJUVANT


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 02.03.2011 US 201161448226 P
01.12.2011 US 201161565980 P

(43) Date of publication of application:
08.01.2014 Bulletin 2014/02

(73) Proprietor: GlaxoSmithKline Biologicals SA
1330 Rixensart (BE)

(72) Inventors:
  • O'HAGAN, Derek
    Cambridge, MA 02139 (US)
  • BAUDNER, Barbara
    53100 Siena (IT)
  • SKIBINSKI, David A.G.
    Singapore 138648 (SG)
  • SINGH, Manmohan
    Cambridge, MA 02139 (US)

(74) Representative: Evans, Stephen John Eves et al
GlaxoSmithKline Global Patents CN925.1 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2007/000322
WO-A1-2009/111337
WO-A1-2010/144734
WO-A2-2005/089794
WO-A1-2007/109813
WO-A1-2010/094663
WO-A1-2012/031140
   
  • BILLAUDELLE H ET AL: "[Triple vaccine without aluminium-"carrier"].", NORDISK MEDICIN 18 OCT 1962 LNKD- PUBMED:13968256, vol. 68, 18 October 1962 (1962-10-18), pages 1339-1340, XP009159265, ISSN: 0029-1420
  • SCHEIFELE D W ET AL: "CAN REDUCTIONS IN DIPHTHERIA TOXOID OR ALUMINUM CONTENT REDUCE THE REACTOGENICITY OF BOOSTE DOSES OF DPT VACCINE?", IMMUNOLOGY AND INFECTIOUS DISEASES, RAPID COMMUNICATIONS OF OXFORD, OXFORD, GB, vol. 5, no. 1, 1 March 1995 (1995-03-01), pages 73-77, XP000891884, ISSN: 0959-4957
  • ABARCA K: "REDUCED-ANTIGEN COMBINED DIPHTHERIA-TETANUS-ACELLULAR PERTUSIS VACCINE (BOOSTRIX) A VIEWPOINT BY KATIA ABARCA", DRUGS, ADIS INTERNATIONAL LTD, NZ, vol. 63, no. 13, 1 January 2003 (2003-01-01), XP008025045, ISSN: 0012-6667
  • SINGH M ET AL: "A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 10, 6 March 2006 (2006-03-06) , pages 1680-1686, XP025151148, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2005.09.046 [retrieved on 2006-03-06]
  • BREWER ET AL: "(How) do aluminium adjuvants work?", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 102, no. 1, 15 January 2006 (2006-01-15), pages 10-15, XP024999104, ISSN: 0165-2478, DOI: 10.1016/J.IMLET.2005.08.002 [retrieved on 2006-01-15]
  • VECCHI SIMONE ET AL: "Aluminum adjuvant dose guidelines in vaccine formulation for preclinical evaluations", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 101, no. 1, January 2012 (2012-01), pages 17-20, XP002675877,
  • WENDORF JANET ET AL: "A comparison of anionic nanoparticles and microparticles as vaccine delivery systems", HUMAN VACCINES, LANDES BIOSCIENCE, UNITED STATES, vol. 4, no. 1, 1 January 2008 (2008-01-01) , pages 44-49, XP001539000, ISSN: 1554-8619
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).